Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II

Company Advances Third In Vivo Protein Replacement Platform™ (IVPRP) Program into Clinical Development RICHMOND, Calif., June 20, 2016 -- (Healthcare Sales & Marketing Network) -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editi... Biopharmaceuticals, FDASangamo BioSciences, Hunter syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news